Safety and efficacy of 3 DMARDs for 2 years of treatment in patients with early rheumatoid arthritis

Safety and efficacy of 3 DMARDs for 2 years of treatment in patients with early rheumatoid arthritis - TRED study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002169

Enrollment

Registered

2009-07-07

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Salazosulfapyridine Bucillamine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatoid Arthritis within 1-year

Exclusion criteria

Exclusion criteria: Autoimmuno disease without RA

Design outcomes

Primary

Measure	Time frame
DAS	—

Secondary

Measure	Time frame
remisshion	—

Countries

Japan

Contacts

Public ContactMitsuhiro Iwahasi

Director RA center

082-423-6661

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026